American Association for Cancer Research
Browse
00085472can102366-sup-sfig_1.pdf (67.38 kB)

Supplementary Figure 1 from Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy

Download (67.38 kB)
journal contribution
posted on 2023-03-30, 20:26 authored by Tommy Martinsson, Therese Eriksson, Jonas Abrahamsson, Helena Caren, Magnus Hansson, Per Kogner, Sattu Kamaraj, Christina Schönherr, Joel Weinmar, Kristina Ruuth, Ruth H. Palmer, Bengt Hallberg
Supplementary Figure 1 from Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy

History

ARTICLE ABSTRACT

Mutations in the kinase domain of the ALK kinase have emerged recently as important players in the genetics of the childhood tumor neuroblastoma. Here, we report the appearance of a novel ALK mutation in neuroblastoma, correlating with aggressive tumor behavior. Analyses of genomic DNA from biopsy samples initially showed ALK sequence to be wild type. However, during disease progression, mutation of amino acid F1174 to a serine within the ALK kinase domain was observed, which correlated with aggressive neuroblastoma progression in the patient. We show that mutation of F1174 to serine generates a potent gain-of-function mutant, as observed in 2 independent systems. First, PC12 cell lines expressing ALKF1174S display ligand-independent activation of ALK and further downstream signaling activation. Second, analysis of ALKF1174S in Drosophila models confirms that the mutation mediates a strong, rough eye phenotype upon expression in the developing eye. Thus, we report a novel ALKF1174S mutation that displays ligand-independent activity in vivo, correlating with rapid and treatment-resistant tumor growth. The study also shows that initial screening in the first tumor biopsy of a patient may not be sufficient and that further molecular analysis, in particular in tumor progression and/or tumor relapse, is warranted for better understanding of the treatment of neuroblastoma patients. Cancer Res; 71(1); 98–105. ©2011 AACR.

Usage metrics

    Cancer Research

    Licence

    Exports